JP2020535448A - Ｒａｎタンパク質の検出のための免役アッセイ - Google Patents

Ｒａｎタンパク質の検出のための免役アッセイ Download PDF

Info

Publication number
JP2020535448A
JP2020535448A JP2020538771A JP2020538771A JP2020535448A JP 2020535448 A JP2020535448 A JP 2020535448A JP 2020538771 A JP2020538771 A JP 2020538771A JP 2020538771 A JP2020538771 A JP 2020538771A JP 2020535448 A JP2020535448 A JP 2020535448A
Authority
JP
Japan
Prior art keywords
ran
poly
subject
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020538771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535448A5 (enExample
Inventor
ラヌム，ラウラ
グエン，リエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of JP2020535448A publication Critical patent/JP2020535448A/ja
Publication of JP2020535448A5 publication Critical patent/JP2020535448A5/ja
Priority to JP2023150846A priority Critical patent/JP2023174663A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2020538771A 2017-09-25 2018-09-25 Ｒａｎタンパク質の検出のための免役アッセイ Pending JP2020535448A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023150846A JP2023174663A (ja) 2017-09-25 2023-09-19 Ｒａｎタンパク質の検出のための免疫アッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563009P 2017-09-25 2017-09-25
US62/563,009 2017-09-25
PCT/US2018/052745 WO2019060918A1 (en) 2017-09-25 2018-09-25 IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023150846A Division JP2023174663A (ja) 2017-09-25 2023-09-19 Ｒａｎタンパク質の検出のための免疫アッセイ

Publications (2)

Publication Number Publication Date
JP2020535448A true JP2020535448A (ja) 2020-12-03
JP2020535448A5 JP2020535448A5 (enExample) 2021-11-04

Family

ID=65811531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538771A Pending JP2020535448A (ja) 2017-09-25 2018-09-25 Ｒａｎタンパク質の検出のための免役アッセイ
JP2023150846A Pending JP2023174663A (ja) 2017-09-25 2023-09-19 Ｒａｎタンパク質の検出のための免疫アッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023150846A Pending JP2023174663A (ja) 2017-09-25 2023-09-19 Ｒａｎタンパク質の検出のための免疫アッセイ

Country Status (5)

Country Link
EP (1) EP3688020A4 (enExample)
JP (2) JP2020535448A (enExample)
AU (2) AU2018338451A1 (enExample)
CA (1) CA3075908A1 (enExample)
WO (1) WO2019060918A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970884A4 (en) 2013-03-14 2016-11-02 Univ Florida DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
JP7526455B2 (ja) 2017-04-17 2024-08-01 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
US20220267776A1 (en) * 2019-07-05 2022-08-25 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
JP7620988B2 (ja) * 2019-09-20 2025-01-24 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
US20240069039A1 (en) * 2019-10-10 2024-02-29 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312395A1 (en) * 2006-09-20 2009-12-17 Queen's University Of Belfast Assay
WO2016025692A1 (en) * 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP2016515208A (ja) * 2013-03-14 2016-05-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
JP2016180665A (ja) * 2015-03-24 2016-10-13 東ソー株式会社 β−ＡＮＰによる心不全の検出方法
JP2017019773A (ja) * 2010-11-30 2017-01-26 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2017055612A1 (en) * 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312395A1 (en) * 2006-09-20 2009-12-17 Queen's University Of Belfast Assay
JP2017019773A (ja) * 2010-11-30 2017-01-26 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
JP2016515208A (ja) * 2013-03-14 2016-05-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
WO2016025692A1 (en) * 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP2016180665A (ja) * 2015-03-24 2016-10-13 東ソー株式会社 β−ＡＮＰによる心不全の検出方法
WO2017055612A1 (en) * 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRCグループＴＯＰ ＞ シー・アール・シー ＞ よくある検査のご質問 ＞ 質問 採血後、全血のまま保, JPN6022033064, 30 June 2013 (2013-06-30), ISSN: 0005237911 *
MARION A GRAY: "Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2", ANN CLIN BIOCHEM, vol. 41, JPN6023019519, 2004, pages 207 - 212, ISSN: 0005061994 *
ご提出材料の保存条件見直しのお知らせ, JPN6022033055, 2011, ISSN: 0005237912 *
研究課題名 ELECSYS CORTISOL試薬を用いた血中コルチゾール定量の臨床性能に関する既存法との互換性評価試, JPN6023019517, 2015, ISSN: 0005061993 *

Also Published As

Publication number Publication date
EP3688020A4 (en) 2021-07-14
EP3688020A1 (en) 2020-08-05
AU2024219412A1 (en) 2024-09-26
CA3075908A1 (en) 2019-03-28
JP2023174663A (ja) 2023-12-08
US20200232925A1 (en) 2020-07-23
AU2018338451A1 (en) 2020-04-02
WO2019060918A8 (en) 2019-04-18
WO2019060918A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
JP2020535448A (ja) Ｒａｎタンパク質の検出のための免役アッセイ
US11939374B2 (en) Treatment of fibrosis
CN102549167B (zh) 作为前列腺癌标志物的磷酸二酯酶4d7
US20240069039A1 (en) Ran proteins as biomarkers in cag/ctg expansion disorders
May et al. Truncating variants in the SHANK1 gene are associated with a spectrum of neurodevelopmental disorders
JP6240919B2 (ja) 加齢または筋萎縮の診断用バイオマーカー
WO2011054644A1 (en) A low density lipoprotein-related protein 1 splice variant as cancer marker
US11022608B2 (en) Compositions and methods for detecting and treating pathological fibroblast cells
JP2021176852A (ja) Ｐｍｖｋを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物
KR102583540B1 (ko) 퇴행성 뇌질환에서 zbtb16의 용도
US12504380B2 (en) Immunoassays for detection of ran proteins
US20200247854A1 (en) Pharmaceutical composition for preventing or treating neurodegenerative disease comprising nckap1 protein or gene encoding same
US20240103015A1 (en) Methods for assaying slc34a2 expression in muscle tissue and treating facioscapulohumeral muscular dystrophy
KR101245112B1 (ko) Ａｐｒｉｎ 유전자 또는 그 발현 단백질, 또는 상기 유전자 발현 감소에 의해 조절되는 단백질을 포함하는 방사선 민감성 마커
WO2014095916A1 (en) Ninjurin-1 as therapeutic target for brain tumor
US20130045537A1 (en) Methods and compositions relating to multiciliate cell differentiation
JPWO2006035702A1 (ja) Ｃペプチド特異的結合分子及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220901

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240119